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Should we affraid of induced cancer in 
group of patients after radical radiotherapy 
of prostate cancer?
Piotr MILECKI, Anna ADAMSKA, Andrzej ROSZAK, Dominika KALETA
ABSTRACT
Radiotherapy is one of the basic methods of radical treatment of prostate cancer. Because of that get-
ting to know all factors of post-radiation complications, and in consequence the possibility to limit 
them, is one of the challenges of contemporary radiotherapy.
One of the potential complications associated with radiation treatment is radiation-induced cancer. 
Despite a whole range of epidemiological analyses there is still lacking a fully credible model that 
would allow one to estimate the magnitude of risk of inducing such cancers. The last decades have 
seen the entry into clinical practice of technologically advanced methods of radiation therapy, such 
as the 3DCRT and IMRT. As the previous epidemiological analyses refer mainly to older radiation tech-
niques, there is still a lack of credible data estimating the risk of inducing secondary cancers for new 
techniques, and in particular IMRT. It should be emphasized that IMRT allows one to escalate the dose, 
which may contribute to the improvement of radiotherapy effectiveness. From this there follows a 
new problem to be solved in future, i.e. how the escalation of the dose may infl uence the magnitude 
of risk of radiation carcinogenesis.
The problem of carcinogenesis may concern the group of younger patients for whom long survival is 
very likely, and the competitive edge of RT relative to surgery, in particular in the aspect of late com-
plications, has to be thoroughly justifi ed.
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INTRODUCTION
Radiotherapy alongside radical prostatectomy 
is among the basic methods of radical treat-
ment of prostate cancer [1, 2, 3]. The increase 
in incidence of prostate cancer in the last de-
cades has resulted in it becoming one of the 
most frequent malignant cancers among men 
[4] in the developed countries. It should also 
be emphasized that the increase of radiother-
apy effectiveness translates into prolonga-
tion of survival of treated patients. Because 
of that, getting to know all factors affecting 
occurrence of potential side-effects of the 
treatment and at the same time actions aimed 
at their maximum limitation are among the 
challenges of contemporary radiotherapy. One 
such complication may be cancer induction by 
radiation. The belief is common that ionizing 
radiation is a carcinogenic factor. An essential 
source of information about the infl uence of 
ionizing radiation on carcinogenesis was the 
observations of individuals who experienced 
exposure to ionizing radiation after the atom 
bomb explosion in Hiroshima [5].
A second group of observations concerns 
patients undergoing medical procedures us-
ing ionizing radiation [6]. It was determined 
on the basis of previously gathered data that 
the time between exposure of healthy tissues 
and the development of cancer is for solid tu-
mours over 10 years, and for leukaemias and 
lymphomas this time is shorter – 5 years [7]. 
Moreover, these observations permitted a 
hypothesis to be formulated stating that the 
relation between administered dose and the 
risk of cancer induction by radiation exhib-
its linear dependence within a dose from 1 
to 2.5 Sv. The carcinogenesis model (linear 
no-threshold (LNT) model) thus established 
is still valid despite a whole range of doubts 
associated with its credibility. Among other 
things, this model does not make possible a 
reliable assessment of the risk of a carcino-
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genic effect in the case of exposure of healthy 
tissues outside the range of doses between 1 
Gy and 3 Gy. In the accepted LNT model as-
sessment of the risk of a carcinogenic effect in 
the case of exposure of healthy tissues to low 
doses, below 1 Gy, cannot be made, because 
the approximate risk of cancer induction was 
derived only by extrapolating the effect from 
the range of higher doses. The effect of higher 
doses of ionizing radiation used principally in 
radiotherapy, i.e. doses exceeding 3 Gy, has 
still not been explained. Generally there are 
two approaches to this problem. In the fi rst 
of them a decline of risk of carcinogenesis, 
caused by increased death of mutated cells 
that are a potential source of carcinogenesis, 
is suggested. On the other hand, in the sec-
ond approach the possibility of a plateau ef-
fect is assumed. In consequence the risk of 
cancer induction by radiation may not depend 
in a directly proportional way on the level of 
the administered dose. However, theoretical 
deliberations themselves, or even in vitro re-
search, still do not permit a real assessment of 
this problem. Moreover, it was assumed in the 
linear model that there is not a threshold dose 
below which ionizing radiation is safe. Such an 
approach may be at odds among other things 
with a different hypothesis, radiation horme-
sis, in which it is assumed that low doses of 
ionizing radiation have simply a favourable ef-
fect on a cell [8].
Previous attempts to estimate the infl uence 
of RT on the risk of induction of a malignant 
tumour in clinical practice have encountered 
a whole range of methodological diffi culties [9, 
10]. In the fi rst place there was the impossibil-
ity of unequivocal classifi cation of a tumour as 
an induced tumour.
This results primarily from the fact that 
the diagnosed cancer does not have charac-
teristic morphological and/or histological fea-
tures typical only for cancer induced by ra-
diotherapy. In consequence of this there also 
follow further methodological problems. The 
only way to determine to what extent RT is re-
sponsible for an increase in the number of in-
duced malignant tumours is a study compar-
ing the incidence of second cancers in a group 
of patients who underwent RT with a group of 
patients who underwent another kind of treat-
ment. Patients after radical prostatectomy are 
taken as the control group. One of the main 
faults of these kinds of analyses is the lack of 
full knowledge of the essential factors respon-
sible for inducing cancer, which means that 
we do not have knowledge of their infl uence 
on the carcinogenetic process.
Ranking foremost among these factors are 
genetic predispositions, environmental fac-
tors (professional exposure, medicinal drugs, 
viral diseases, hormonal profi le of patient) 
and addictions, e.g. smoking [11]. It should be 
emphasized that ionizing radiation is only one 
of numerous factors responsible for carcino-
genesis. Despite the limitations mentioned 
above, epidemiological analysis is still the 
most valuable source of knowledge about ra-
diotherapy as a carcinogenic factor in patients 
with prostate cancer.
Factors that may increase 
the risk of cancer induction 
by radiotherapy
New techniques of irradiation
The introduction of technologically advanced 
radiotherapy in the last decades has led some 
researchers to conjecture that such therapy 
might be associated with a greater risk of 
inducing cancer than in a two-dimensional 
technique. This hypothesis is grounded in the 
fact that it is precisely within doses between 
1 Gy and 4 Gy that the greatest risk of cancer 
induction by radiation can be expected. Tran-
sition from the conventional 2D radiotherapy 
to 3D conformal radiotherapy enabled reduc-
tion of the volume of healthy tissues receiving 
high doses of radiation, and on the other hand 
led to the possibility to administer a higher 
dose to a tumour together with parallel limi-
tation of the dose to healthy tissues adjacent 
to the tumour [12]. Because of the above the 
modern techniques of radiotherapy may lead 
to a drop in the number of sarcomas that de-
velop within the volume of tissues exposed to 
high doses of radiation [13, 14]. Also, although 
less certain, a small fall in the number of can-
cers within areas adjacent to the tumour can 
be expected.
On the other hand, in the conformal tech-
nique, and in particular IMRT, it is neces-
sary to apply a greater number of therapeutic 
beams, which is associated (as shown by the 
histograms) with the deposition of low doses, 
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much smaller than 2 Gy, in a greater volume 
of healthy tissue.
Additionally, in this technique there is an 
increase in monitor units by a factor of 2 to 
3, which consequently increases the expo-
sure of the whole body to ionizing radiation. 
Additional exposure of the patient may result 
from increased leakage of radiation through 
the accelerator head. Both these facts have 
important consequences for the risk of radi-
ation-induced cancer. According to theoreti-
cal assumptions, IMRT may increase the risk 
of development of secondary cancers almost 
twofold in comparison with conventional con-
formal radiotherapy, i.e. from 1% to 1.75% for 
patients surviving over 10 years, and this level 
may potentially increase in the case of longer 
survival (in younger patients) [13]. Taking 
into account that sarcomas appear only within 
healthy tissues subjected to irradiation with a 
high dose, it does not seem that between IMRT 
and 3D there was a signifi cant difference in 
respect of inducing these tumours. However, 
in the case of using IMRT an increase in the 
number of cancers, in particular outside the 
close surroundings of the tumour, can be ex-
pected.
The next factor that may in future increase 
the risk of cancer induction by radiation is 
the improvement of therapy effectiveness that 
would translate to prolongation of the time of 
survival of patients beyond the typical latency 
period of carcinogenesis. In the developed 
countries, in the last two decades, a signifi -
cant improvement of survival of patients with 
prostate cancer has been noted, to which the 
improvement of radiotherapy effectiveness 
might have contributed [15]. An additional 
factor associated with modern radiotherapy 
techniques that may increase the risk of radi-
ation-induced cancer is the use of additional 
doses of radiation in the process of verifi ca-
tion of the irradiation treatment [16]. The dose 
administered through critical organs during a 
single computed tomography examination in 
a patient during the planning of radiotherapy 
varies between 1 mGy and 40 mGy depend-
ing on the volume anticipated for irradiation 
and technical parameters of the apparatus 
[17]. The next source of additional radiation 
dosage, which is from 10 mGy to 20 mGy, is 
the imaging process verifying geometric cor-
rectness of irradiation, and it should be em-
phasized that during the whole course of ir-
radiation it is performed many times [18]. 
In general, the more complicated the plan of 
irradiation treatment, the higher the dose of 
ionizing radiation that will be deposited out-
side the target volume. It still remains an un-
solved issue how the above doses may infl u-
ence the risk of inducing cancer in the context 
of the whole irradiation process. Exposure to 
additional radiation will probably increase to-
gether with the progress in irradiation tech-
niques and diagnostics applied in the planning 
process of radiotherapy, e.g. positron emission 
tomography [19]. In that case, should all these 
doses be registered, considering also doses 
from the diagnostic process? A clinician has 
the obligation to assess and optimise all expo-
sures to radiation in every situation. However, 
in clinical practice this is extremely diffi cult, 
and basically unfeasible. Therefore we should 
aspire more to develop generally applicable 
rules of practice, remembering that the more 
complicated the treatment, the higher the ad-
ditional dose of ionizing radiation the patient 
will receive.
The most important epidemiological 
research assessing the risk of second 
cancer related to radiotherapy
According to Harrison et al. [20] the risk of 
radiation-induced cancer in the case of treat-
ment with irradiation of prostate cancer up to 
the dose of 74 Gy is between 2.2 and 8.2 per 10 
000 patients a year. Movsas et al. [21] made an 
analysis of the risk of inducing cancer, based 
on observation data of 18 135 patients regis-
tered in the Connecticut Tumor Registry and 
543 patients from Fox Chase Cancer Center. 
The authors compared the number of second-
ary malignant cancers diagnosed in the group 
of 18 135 patients with prostate cancer after 
surgery with the number of identical cancers 
noted in the group of 543 patients in which RT 
was applied.
In the group that was not subjected to radio-
therapy in 1053 (5.8%) patients a secondary 
primary cancer was noted, and in the group 
of patients who underwent radiotherapy a sec-
ondary primary cancer was noted in 31 (5.7%) 
patients. A fact worth noting is that among 
these 31 patients in whom cancer occurred, as 
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many as 82% had a medical history of smok-
ing and/or drinking alcohol. The research 
shows that although the risk of development 
of cancer after previous treatment of prostate 
cancer increases with time, it is not typically 
different in any period of time between the 
above-mentioned groups of patients. Only the 
number of melanomas revealed in the group 
of patients subjected to radiotherapy was 
signifi cantly higher in comparison with the 
quantity expected for a comparable age group 
(p<0.001). It should be noted in summary that 
5 out of 31 cancers (16%) appeared in the ir-
radiated fi eld (4 bladder cancers and 1 rectum 
cancer), 4 of these within the fi rst 3 years from 
the treatment and 1 not until 9 years after ra-
diotherapy. The other 84% of cancers devel-
oped outside the irradiated area. The authors 
emphasize that for the period up to 10 years 
after irradiation there is not an increased risk 
of cancer development. It is essential that this 
risk is not higher in younger patients with the 
disease localized to the prostate (< pT2c), pa-
tients who usually have a choice between sur-
gical treatment and radiotherapy. In the study 
by Neugut et al. [22] 141 761 patients with 
diagnosed prostate cancer were subjected to 
analysis. In this group RT was applied in 34 
889 (24.6%) patients, and in the other 106 872 
(75.4%) surgical treatment was performed.
The authors, within the eight-year observa-
tion period, found in patients treated by irra-
diation a signifi cant increase in incidence of 
malignant bladder cancers (RR=1.5, 95% CI 
[1.1–1.2]).
Brenner et al. [23] carried out an analy-
sis of incidence of secondary cancers in two 
groups of patients, i.e. surgically treated or 
RT treated. In the group of 70 539 patients in 
whom only surgical treatment was performed 
the authors observed 5055 cases of secondary 
cancers.
Meanwhile in the second group, comprising 
51 584 patients, in whom only RT was applied, 
3549 cases of secondary cancers were noted. 
In the above study stratifi cation of patients was 
done with reference to time of cancer becom-
ing apparent, age and cancer location. The au-
thors state in the summary that RT involves a 
6% increase of the risk of occurrence of solid 
tumours (p=0.02), and together with the pro-
longation of the time of observation to 5 and 10 
years this risk increases respectively to 15% 
and 34%. Organs in which an increase in the 
number of registered cancers was noted were 
(in order) bladder, rectum and lungs. More-
over, an increased incidence of sarcomas was 
observed only in those healthy tissues which 
received a high dose. The authors did not note 
increased incidence of leukaemia. Noteworthy 
is the observed increase in incidence of lung 
cancers, and it should be emphasized that the 
authors excluded the difference in intensity 
of the habit of smoking between the analyzed 
groups of patients. It was stated in summary 
that the general risk of occurrence of induced 
cancer in patients treated with radiation was 
1/290, and in patients who survived over 10 
years after the completion of RT this risk in-
creased to 1/70. The analysis carried out by 
Pickles et al. [24] was based on data from the 
register of cases in the period 1984 to 2000, 
during which generally 39 261 cases of pros-
tate cancer were noted. Among this group in 
9890 RT was applied. Comparison of the num-
bers of secondary cancers in the irradiated 
group with those surgically treated shows that 
a signifi cant increase of risk of cancer after 
RT was noted only with respect to colorec-
tal cancer (RR=1.21, p=0.03) and sarcomas 
(RR=2.49, p=0.016). It is worth noting the ob-
served increase of risk of the occurrence of 
secondary cancers in younger patients (1/70) 
in comparison with patients of more advanced 
age (1/220). The above differences may result 
from the fact that RT in younger patients, due 
to their longer time of survival, paradoxically 
creates a greater risk of induced cancer be-
coming apparent.
The authors state that RT causes a small in-
crease in incidence of secondary cancers that 
is only 6% (not reaching the level of statistical 
signifi cance).
Wayne et al. [25] did the fi rst assessment 
of the infl uence of irradiation on the risk of 
inducing rectal cancer. Among 33 831 irradi-
ated patients with prostate cancer 243 (0.7%) 
were noted with rectal cancer. In comparison, 
in the group of 167 607 patients surgically 
treated this cancer was found in 578 (0.3%), 
and in the group of 36 335 persons who were 
neither operated on nor irradiated it was found 
in 227 (0.8%) persons. The statistical analysis 
revealed that the age difference between the 
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researched groups was the most signifi cant 
parameter infl uencing the differences in the 
noted numbers of rectal cancers. After con-
sideration of the mentioned age difference, 
the authors did not fi nd any more signifi cant 
increase in risk of occurrence of rectal cancer 
in patients who underwent irradiation.
Moon [26] et al. studied the size and sig-
nifi cance of the observed relation between 
cases of secondary cancer after 5 years 
from RT in the population of men with pros-
tate cancer who were in the SEER database. 
Patients treated with RT had a statistically 
higher risk of developing secondary cancer 
in areas potentially connected with irradia-
tion, including the bladder (HR: 1.63) and 
rectum (HR: 1.60). Patients after RT had 
moreover higher risk of cancer development 
in upper parts of the body which were not 
connected with exposure to higher doses of 
radiation: caecum (1.63), transverse colon 
(1.85), brain (1.83), stomach (1.38), mela-
noma (1.29), lung and bronchi (1.25). As the 
authors point out, RT is still connected with 
the risk of occurrence of secondary cancers, 
including leukaemias, sarcomas, thyroid, 
lung and bladder cancers. The next impor-
tant conclusion resulting from this study is 
that the latency period between exposure 
and cancer appearance exceeds 5 years, and 
on average is 15 years. Secondary cancers 
may appear in the radiation fi eld, but can-
cers which appear in a period up to 5 years 
cannot be counted as associated with RT. 
Radiotherapy is inevitably connected with 
irradiation of organs and healthy tissues 
located outside the tumour; however, con-
formal techniques may help to reduce these 
side effects. Most observed cancers induced 
by radiation were within the margins of the 
target volume (by defi nition this is an area 
up to 5 cm from the tumour border).
It should be emphasized that ionizing radia-
tion is only one of the factors affecting the risk 
of cancer induction alongside those such as 
smoking and other environmental loads that 
may infl uence the frequency and risk of devel-
oping subsequent cancers not included in the 
study. Apart from that the SEER database it-
self is not an infallible source of data because 
cases of secondary cancer are often not cor-
rectly recorded in it (some of them have not 
been entered at all; there is also a lack of their 
correct substantiation, in particular when the 
data derive from a death certifi cate that does 
not include detailed information).
Schneider [27] made an attempt to estimate 
the risk of occurrence of secondary cancers 
depending on the level of the administered 
dose of radiation in patients treated with con-
formal radiotherapy (3DCRT, IMRT) and pro-
ton beam irradiation. With this aim radiother-
apy of 23 patients with prostate cancer was 
planned according to the following outline: 7 
patients with fourfi eld technique, 8 patients 
with IMRT technique and 8 patients with the 
use of proton therapy (two lateral fi elds). The 
range of total doses applied in the research 
was from 70 to 100 Gy, with application of a 
fractional dose of 1.8 Gy. The risk of occur-
rence of cancer induced by radiation was pre-
sented as a function of dose and probability 
of tumour control. The authors showed that 
administered doses of 100 Gy in comparison 
with 70 Gy caused greater risk of developing 
secondary cancer by 18.4%.
On the other hand, the increased risk of de-
velopment of secondary cancer associated with 
a higher dose may be recompensed by achiev-
ing greater local effectiveness of therapy. The 
authors show in the summary that the risk of 
induced cancer occurring after application of 
a dose of 100 Gy may be even smaller than the 
risk that we may expect when applying a dose 
of 70 Gy. To summarize, further increase of 
the dose level may intensify induction of car-
cinogenesis but at the same time increases the 
probability of tumour control (TCP – tumour 
control probability).
Proton therapy is in this case a method of 
choice because it reduces almost by half the 
risk of secondary cancers in comparison with 
photon therapy. The results of this study show 
that escalation of the dose in the treatment of 
prostate cancer increases the risk of induc-
ing secondary cancer. The risk of secondary 
cancers with the application of a dose of 100 
Gy for IMRT in comparison with 3DCRT with 
the application of 70 Gy may be increased by 
a maximum of 25%. The estimated number of 
post-radiation solid tumours would increase 
from 34/10 000 to 43/10 000. However, consid-
ering the higher percentage of cure with the 
application of higher doses, it may be assumed 
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that the escalation of the dose creates a signif-
icantly higher chance for cure. The use of pro-
tons in this situation reduces almost twofold 
the risk of secondary cancer in comparison 
with 3DCRT, which means that this form of 
irradiation would give the greatest potential 
therapeutic benefi t.
CONCLUSIONS
The choice of the method of treatment for pros-
tate cancer is usually dictated by the effective-
ness of the proposed treatment and potential 
side effects. Irradiation treatment is connect-
ed with a small risk of inducing cancer. Con-
sidering the age structure of treated patients, 
it can be assumed that from the practical point 
of view this risk can be omitted. However, in 
future, together with the increased survival 
of patients and more frequent qualifi cation for 
treatment at younger age, it may be necessary 
to consider the assessment of the described 
risk in the strategic approach.
Because there still exists a whole range of 
ambiguities concerning the assessment of re-
sults of irradiation treatment, it is necessary 
in future to create a systematic prospective 
programme aimed at determining the risk of 
cancer induction by radiation.
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